Navigation Links
Estrogen Levels in Blood Predict Breast Cancer's Return

Study found women who had a recurrence had twice as much of the hormone in their system

THURSDAY, March 6 (HealthDay News) -- New research shows that women who experienced a recurrence of their breast cancer had almost twice as much estrogen in their blood as women who remained cancer-free after treatment.

This indicates that circulating estrogen levels contribute to a recurrence as much as the initial malignancy does.

That information is not entirely new, said Dr. Jennifer Wu, an obstetrician/gynecologist at Lenox Hill Hospital in New York City. "That's the reason we use drugs that help to lower estrogen levels. Estrogen causes increased cell division; we think it can perhaps start breast cancer," she said. "But this is a good study in that it has a lot of patients and proves that they have a demonstrable increase in estrogen levels over patients who don't have a recurrence."

Where there's a problem, there's also often a solution.

"Anti-estrogen drugs can only have so much impact," said study author Cheryl Rock, a professor of family and preventive medicine at the University of California, San Diego, School of Medicine. "There are two things apart from these drugs that can help to lower estrogen, or we believe it can, because it can in the general population. One is moderate to vigorous exercise, and the other is healthy weight management, achieving an ideal weight."

The hormone estrogen is produced not only by the ovaries, but also by fat tissue.

Previous research has shown that estrogen contributes to the risk of primary breast cancer in postmenopausal women, but there has been less evidence of the role of estrogen in cancer recurrence.

"The relationship between circulating estrogen and risk for primary breast cancer is very well-established, but there were surprisingly few studies in which estrogen levels have been measured in breast cancer survivors," Rock explained.

This study, published in the March issue of Cancer Epidemiology, Biomarkers & Prevention, followed 153 pairs of women who had had breast cancer (one in each pair experienced a recurrence, while one did not) for more than seven years.

Two-thirds of the participants were using tamoxifen, a drug which interferes with estrogen's activity in the body.

In the end, women with more circulating estrogen were more likely to have a recurrence.

There may be other factors at play also, Rock said. For instance, sex hormone-binding globulin basically makes estrogen available to get into tissue. "If estrogen is bound to that protein, it's not going to float right over to the cell," Rock said. "When people are overweight, they have higher blood levels of insulin, which suppresses synthesis of that protein, so exercise not only is related to actually helping weight management but, because it lowers insulin, it might make the hormonal situation look better."

And don't rule out existing anti-estrogen drugs, experts added.

"This study justifies the use of drugs that help decrease estrogen levels like tamoxifen and aromatase inhibitors," Wu said. "[In the future], we may want to titrate different levels of anti-estrogen medications. Right now, we have a standard dosage for everyone, whereas women who are heavier or other women who may have higher estrogen levels for one reason or another may need larger doses."

More information

Visit the National Cancer Institute for more on breast cancer.

SOURCES: Cheryl L. Rock, Ph.D., professor, family and preventive medicine, University of California, San Diego, School of Medicine; Jennifer Wu, M.D., obstetrician/gynecologist, Lenox Hill Hospital, New York City; March 2008, Cancer Epidemiology, Biomarkers & Prevention

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annual Meeting
2. Gene May Influence Breast Cancer-Estrogen Link
3. Cholesterol byproduct blocks heart health benefits of estrogen
4. UCLA study identifies designer estrogen as potential MS drug
5. New link between estrogen and breast cancer
6. Atypical protein kinase C stabilizes SRC-3 levels in breast cancer cells
7. Moderate Aerobic Fitness Levels May Cut Stroke Risk
8. Novel link between excessive nutrient levels and insulin resistance
9. Silymarin does not affect virus activity or ALT levels in
10. In Unfolding Budget Debate, Alliance to Spotlight Flawed MedPAC Policy Guidance, Failure to Evaluate Medicaid Margins in Recommending Medicare Funding Levels
11. New findings show Enbrel significantly reduced levels of C-reactive protein
Post Your Comments:
Related Image:
Estrogen Levels in Blood Predict Breast Cancer's Return
(Date:6/27/2016)... ... June 27, 2016 , ... recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: